Abstract
Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.
Keywords: Direct-acting antivirals, resistance, cirrhosis, difficult-to-cure, hepatitis C virus.
Current Drug Targets
Title:Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
Volume: 18 Issue: 7
Author(s): Jordan J. Feld*
Affiliation:
- Toronto Centre for Liver Disease, University of Toronto, 200 Elizabeth Street, 9EN, Toronto, ON, M5G 2C4,Canada
Keywords: Direct-acting antivirals, resistance, cirrhosis, difficult-to-cure, hepatitis C virus.
Abstract: Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.
Export Options
About this article
Cite this article as:
Feld J. Jordan*, Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150825111314
DOI https://dx.doi.org/10.2174/1389450116666150825111314 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Mitochondrial Functionality and Chemical Compound Action on Sperm Function
Current Medicinal Chemistry Thyroid Metastases from Breast Cancer Case Report and Literature Review
Current Cancer Drug Targets Patented Herbal Formulations and their Therapeutic Applications
Recent Patents on Drug Delivery & Formulation Image Processing Pitfalls in Vendor Adaptive Radiotherapy Software with Tomotherapy-like Systems: Feedback from Clinical Case Reports
Current Medical Imaging Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets A Study on the Bio-responses of a Freshwater Snail (<i>Biomphalaria alexandrina</i>) to Fungal-derived Compounds
Recent Advances in Anti-Infective Drug Discovery The Role of Neuronal Pathways in Gastrointestinal Cancers: Targets for Prevention and Treatment
Letters in Drug Design & Discovery Recent Developments in the Synthesis and Biological Activity of Muramylpeptides
Current Medicinal Chemistry Anticancer Perspectives on the Fungal-Derived Polyphenolic Hispolon
Anti-Cancer Agents in Medicinal Chemistry Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities
Drug Metabolism Letters Meet Our Editorial Board Member
Current Medicinal Chemistry Nano-based Herbal Medicine: A New Candidate for Prostate Cancer Treatment?
Current Traditional Medicine Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry